Jump to content

Ulocuplumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Fswitzer4 (talk | contribs) at 16:18, 25 January 2021 (Added UNII). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ulocuplumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetC-X-C chemokine receptor type 4
Clinical data
Other namesMDX-1338
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6486H9960N1720O2046S46
Molar mass146243.78 g·mol−1

Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]

This drug was developed by Bristol-Myers Squibb.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.



Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ulocuplumab&oldid=1002681155"